Compare · AZN vs PTIX
AZN vs PTIX
Side-by-side comparison of AstraZeneca PLC (AZN) and Protagenic Therapeutics Inc. (PTIX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and PTIX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN carries a market cap of $286.03B.
- AZN has been more active in the news (18 items in the past 4 weeks vs 3 for PTIX).
- AZN has more recent analyst coverage (25 ratings vs 1 for PTIX).
- Company
- AstraZeneca PLC
- Protagenic Therapeutics Inc.
- Price
- -
- -
- Market cap
- $286.03B
- -
- 1M return
- +10.68%
- -
- 1Y return
- +106.42%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 18
- 3
- Recent ratings
- 25
- 1
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Protagenic Therapeutics Inc.
Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.
Latest AZN
- Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
- FDA Approval for KLYGEFA issued to ALEXION PHARM
- AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,292 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Enhertu® Wins 2026 International Prix Galien Award for Best Biotechnology Product
- AstraZeneca results: 9M and Q3 2026
Latest PTIX
- Protagenic Therapeutics Announces Private Placement of Up to $5 Million to Advance PT00114 into Its First U.S. Clinical Trial in Generalized Anxiety Disorder
- SEC Form 10-Q filed by Protagenic Therapeutics Inc.
- Protagenic Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $13,000 worth of shares (20,000 units at $0.65), increasing direct ownership by 37% to 73,533 units (SEC Form 4)
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $9,811 worth of shares (16,634 units at $0.59), increasing direct ownership by 45% to 53,533 units (SEC Form 4)
- Protagenic Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- EXEC. CHAIR & PRINCIPAL OFF Armen Garo H bought $945 worth of shares (2,700 units at $0.35), increasing direct ownership by 8% to 36,899 units (SEC Form 4)
- Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder
- SEC Form 10-Q filed by Protagenic Therapeutics Inc.
- SEC Form NT 10-Q filed by Protagenic Therapeutics Inc.